Literature DB >> 24625199

Sex differences in benzodiazepine use in the HIV-infected population.

Sarah E Wixson1, Emily S Brouwer.   

Abstract

In the HIV-infected population there is a high prevalence of psychiatric disorders, conditions that often coexist with drug and alcohol dependence. Symptoms associated with psychiatric disorders are frequently managed with benzodiazepines, a class of medication often abused. We examined whether HIV-infected patients were more likely to fill a benzodiazepine prescription than their uninfected counterparts using a privately insured, nationally representative sample receiving clinical care between January 2007 and December 2009. Odds ratios (OR) and 95% confidence intervals (CI) to quantify the likelihood of receiving a benzodiazepine were calculated using multivariate logistic regression models. We examined the presence of interaction between HIV infection and sex using backwards elimination and by comparing stratum-specific OR to identify clinically meaningful differences. Overall, 323,796 beneficiaries were included in the sample, of which 723 were HIV infected. Bivariate analyses showed that compared to the uninfected sample, HIV-infected patients were more likely to have filled a benzodiazepine prescription (24% vs. 19%) during the study period. HIV-infected patients were also more likely to be male (80% vs. 44%), black (21% vs. 7%) and have a diagnosis of depression (12% vs. 8%) or insomnia (6% vs. 3%) than were uninfected patients. Adjusted for other covariates, HIV infection was associated with an increase (OR): 1.68, 95% CI: 1.39, 2.02) in the likelihood of filling a benzodiazepine prescription. When stratified by sex, HIV-infected males were more likely (OR: 1.68, 95% CI: 1.05, 2.67) than uninfected males to fill a benzodiazepine prescription while there was no observed difference in the likelihood of filling a benzodiazepine prescription between HIV-infected and uninfected females (OR: 1.12, 95% CI: 0.73, 1.70). Our findings suggest that HIV-infected patients, particularly HIV-infected males, are more likely to fill benzodiazepine prescriptions than their uninfected counterparts, highlighting the need for further research to investigate reasons for these observed differences.

Entities:  

Keywords:  HIV; benzodiazepine; drug utilisation; psychiatric disorders; sex differences

Mesh:

Substances:

Year:  2014        PMID: 24625199      PMCID: PMC4087069          DOI: 10.1080/09540121.2014.894615

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  22 in total

1.  Anxiety and HIV infection.

Authors:  A Elliott
Journal:  STEP Perspect       Date:  1998

2.  Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users.

Authors:  Julia H Arnsten; Penelope A Demas; Richard W Grant; Marc N Gourevitch; Homayoon Farzadegan; Andrea A Howard; Ellie E Schoenbaum
Journal:  J Gen Intern Med       Date:  2002-05       Impact factor: 5.128

Review 3.  Appropriate use and regulatory control of benzodiazepines.

Authors:  R I Shader; D J Greenblatt; M B Balter
Journal:  J Clin Pharmacol       Date:  1991-09       Impact factor: 3.126

4.  Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance.

Authors:  N Singh; C Squier; C Sivek; M Wagener; M H Nguyen; V L Yu
Journal:  AIDS Care       Date:  1996-06

5.  Benzodiazepine use among depressed patients treated in mental health settings.

Authors:  Marcia Valenstein; Kiran Khanujua Taylor; Karen Austin; Helen C Kales; John F McCarthy; Frederic C Blow
Journal:  Am J Psychiatry       Date:  2004-04       Impact factor: 18.112

6.  Stigma, social risk, and health policy: public attitudes toward HIV surveillance policies and the social construction of illness.

Authors:  Gregory M Herek; John P Capitanio; Keith F Widaman
Journal:  Health Psychol       Date:  2003-09       Impact factor: 4.267

7.  High prevalence of insomnia in an outpatient population with HIV infection.

Authors:  M L Rubinstein; P A Selwyn
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998-11-01

8.  Antiretroviral therapy and health care utilization: a study of privately insured men and women with HIV disease.

Authors:  Fred J Hellinger; William E Encinosa
Journal:  Health Serv Res       Date:  2004-08       Impact factor: 3.402

9.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang
Journal:  JAMA       Date:  2003-06-18       Impact factor: 56.272

10.  Prescription psychotropic medication use among the U.S. adult population: results from the third National Health and Nutrition Examination Survey, 1988-1994.

Authors:  Ryne Paulose-Ram; Bruce S Jonas; Denise Orwig; Marc A Safran
Journal:  J Clin Epidemiol       Date:  2004-03       Impact factor: 6.437

View more
  4 in total

1.  The epidemiology of benzodiazepine misuse: A systematic review.

Authors:  Victoria R Votaw; Rachel Geyer; Maya M Rieselbach; R Kathryn McHugh
Journal:  Drug Alcohol Depend       Date:  2019-05-07       Impact factor: 4.492

2.  The association between benzodiazepine use and greater risk of neurocognitive impairment is moderated by medical burden in people with HIV.

Authors:  Erin E Sundermann; Rowan Saloner; Anna Rubtsova; Annie L Nguyen; Scott Letendre; Raeanne C Moore; Mariana Cherner; Qing Ma; María J Marquine
Journal:  J Neurovirol       Date:  2022-04-07       Impact factor: 3.739

3.  Benzodiazepine Use Is Associated With an Increased Risk of Neurocognitive Impairment in People Living With HIV.

Authors:  Rowan Saloner; David J Grelotti; Griffin Tyree; Erin E Sundermann; Qing Ma; Scott Letendre; Robert K Heaton; Mariana Cherner
Journal:  J Acquir Immune Defic Syndr       Date:  2019-12-15       Impact factor: 3.771

4.  Alprazolam Prompts HIV-1 Transcriptional Reactivation and Enhances CTL Response Through RUNX1 Inhibition and STAT5 Activation.

Authors:  Angel Lin; Weam Othman Elbezanti; Alexis Schirling; Adel Ahmed; Rachel Van Duyne; Simon Cocklin; Zachary Klase
Journal:  Front Neurol       Date:  2021-07-22       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.